Avanir Restructures After Ending Deals With Novartis, AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
Plan to reduce operating expenses by $20 million will include some headcount reductions, CEO Katkin tells “The Pink Sheet” DAILY